Mesoblast's long-term protection
Wednesday, 16 July, 2008
Mesoblast [ASX: MSB] has been granted a US patent through to 2019 for its Mesenchymal Precursor Cells [MPC], proprietary adult stem cells developed by Mesoblast and its sister company Angioblast Systems.
The patent ensures only Mesoblast and Angioblast can commercialise MPCs in the US.
MPCs were first identified in Australia, at the Hanson Institute in Adelaide. They are capable of repairing and regenerating a host of tissue types, including bone, cartilage, fat, blood vessels and heart muscle.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
